SG10201404903XA - Variant immunoglobulins with improved manufacturability - Google Patents

Variant immunoglobulins with improved manufacturability

Info

Publication number
SG10201404903XA
SG10201404903XA SG10201404903XA SG10201404903XA SG10201404903XA SG 10201404903X A SG10201404903X A SG 10201404903XA SG 10201404903X A SG10201404903X A SG 10201404903XA SG 10201404903X A SG10201404903X A SG 10201404903XA SG 10201404903X A SG10201404903X A SG 10201404903XA
Authority
SG
Singapore
Prior art keywords
improved manufacturability
variant immunoglobulins
immunoglobulins
variant
manufacturability
Prior art date
Application number
SG10201404903XA
Other languages
English (en)
Inventor
Andreas Arnell
José Jimenez
Rebecca Michael
Yvette Stallwood
Jesús Zurdo
Original Assignee
Lonza Biologics Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41171774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201404903X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lonza Biologics Plc filed Critical Lonza Biologics Plc
Publication of SG10201404903XA publication Critical patent/SG10201404903XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201404903XA 2009-08-21 2010-08-20 Variant immunoglobulins with improved manufacturability SG10201404903XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0914691.1A GB0914691D0 (en) 2009-08-21 2009-08-21 Immunoglobulin variants
US24171709P 2009-09-11 2009-09-11

Publications (1)

Publication Number Publication Date
SG10201404903XA true SG10201404903XA (en) 2014-10-30

Family

ID=41171774

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201404903XA SG10201404903XA (en) 2009-08-21 2010-08-20 Variant immunoglobulins with improved manufacturability
SG2012009114A SG178340A1 (en) 2009-08-21 2010-08-20 Variant immunoglobulins with improved manufacturability

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012009114A SG178340A1 (en) 2009-08-21 2010-08-20 Variant immunoglobulins with improved manufacturability

Country Status (16)

Country Link
US (2) US8951516B2 (fr)
EP (1) EP2467400B1 (fr)
JP (1) JP5901522B2 (fr)
KR (1) KR20120056850A (fr)
CN (2) CN102596994A (fr)
AU (1) AU2010284841A1 (fr)
BR (1) BR112012003571A2 (fr)
CA (1) CA2771465A1 (fr)
DK (1) DK2467400T3 (fr)
EA (1) EA201290063A1 (fr)
GB (1) GB0914691D0 (fr)
IL (1) IL217993A0 (fr)
MX (1) MX2012002100A (fr)
SG (2) SG10201404903XA (fr)
TW (1) TW201116626A (fr)
WO (1) WO2011021009A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
DK2275443T3 (en) 2008-04-11 2016-02-08 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repetitively binding to two or more antigen molecules
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
KR102385507B1 (ko) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
EP2889377B1 (fr) 2012-08-24 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Variant de la région fc spécifique à fcyriib
WO2014030750A1 (fr) 2012-08-24 2014-02-27 中外製薬株式会社 ANTICORPS Fc SPÉCIFIQUE À FcyRII DE SOURIS
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
EP3209684B1 (fr) * 2014-10-24 2020-12-23 F.Hoffmann-La Roche Ag Humanisation d'anticorps à base d'angle vh-vl-interdomaine
TWI831538B (zh) 2014-12-19 2024-02-01 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
WO2016131769A2 (fr) 2015-02-16 2016-08-25 Lonza Ltd Anticorps
EP3394098A4 (fr) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine et procédés d'utilisation
WO2018005682A2 (fr) 2016-06-29 2018-01-04 Checkpoint Therapeutics, Inc. Anticorps spécifiques de pd-l1 et procédés pour les utiliser
IL264626B (en) 2016-08-05 2022-07-01 Chugai Pharmaceutical Co Ltd A preparation for the prevention or treatment of diseases related to il-8
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP7508368B2 (ja) 2018-03-15 2024-07-01 中外製薬株式会社 ジカウイルスに対して交差反応性を有する抗デングウイルス抗体および使用方法
EP3772518A1 (fr) * 2019-08-07 2021-02-10 Merus N.V. Domaines variables humains modifiés
JP2024502832A (ja) * 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ， インコーポレイテッド 高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
MXPA01007170A (es) * 1999-01-15 2002-07-30 Genentech Inc Variantes de polipeptidos con funcion efectora alterada.
US7700751B2 (en) * 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
WO2004065417A2 (fr) 2003-01-23 2004-08-05 Genentech, Inc. Procedes de production d'anticoprs humanises et d'amelioration du rendement d'anticorps ou de fragments de liaison d'antigenes en culture cellulaire
CA2525370A1 (fr) 2003-05-06 2004-11-25 The Scripps Research Institute Molecules de liaison a echange de domaine, procedes d'utilisation et procedes de production
RU2005140664A (ru) * 2003-06-27 2007-08-27 Байорен, Инк. (Us) Просматривающий мутагенез
ATE552276T1 (de) * 2003-11-01 2012-04-15 Merck Patent Gmbh Modifizierter anti-cd52-antikörper
ES2550311T3 (es) 2003-11-05 2015-11-06 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
GB0325817D0 (en) * 2003-11-05 2003-12-10 Univ Cambridge Tech Method and apparatus for assessing polypeptide aggregation
EP1737890A2 (fr) 2004-03-24 2007-01-03 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
ATE500276T1 (de) 2004-12-30 2011-03-15 Us Gov Health & Human Serv Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
NZ584769A (en) 2007-09-28 2011-09-30 Chugai Pharmaceutical Co Ltd Anti-glypican-3 antibody having improved kinetics in plasma
CA2727937A1 (fr) * 2008-06-20 2009-12-23 Massachusetts Institute Of Technology Immunoglobulines presentant une agregation reduite
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
IL217993A0 (en) 2012-03-29
CN102596994A (zh) 2012-07-18
JP2013502402A (ja) 2013-01-24
TW201116626A (en) 2011-05-16
US9290563B2 (en) 2016-03-22
US8951516B2 (en) 2015-02-10
EP2467400B1 (fr) 2018-01-24
MX2012002100A (es) 2012-06-19
KR20120056850A (ko) 2012-06-04
JP5901522B2 (ja) 2016-04-13
WO2011021009A1 (fr) 2011-02-24
DK2467400T3 (en) 2018-05-14
SG178340A1 (en) 2012-03-29
BR112012003571A2 (pt) 2016-11-22
CA2771465A1 (fr) 2011-02-24
EP2467400A1 (fr) 2012-06-27
US20150104449A1 (en) 2015-04-16
US20120148568A1 (en) 2012-06-14
GB0914691D0 (en) 2009-09-30
EA201290063A1 (ru) 2012-12-28
AU2010284841A1 (en) 2012-03-15
CN106986935A (zh) 2017-07-28

Similar Documents

Publication Publication Date Title
IL217993A0 (en) Variant immunoglobulins with improved manufacturability
ZA201202612B (en) Combination
EP2377932A4 (fr) ANTICORPS ANTI-Siglec-15
EP2520815A4 (fr) Bouchon linéaire
GB0908027D0 (en) Spetrophotometer with no moving parts
IL219103A0 (en) Combination
IL219786A0 (en) Combination
ZA201202494B (en) Combination
ZA201202173B (en) Combination
EP2481868A4 (fr) Élément pour l'atténuation du bruit
GB201011356D0 (en) Ventalation arrangements
ZA201202495B (en) Combination
ZA201202258B (en) Combination
IL218801A0 (en) Combination
GB0914172D0 (en) Fixing
GB0901800D0 (en) Fixing element
GB201206482D0 (en) #magnotherapy
GB0916277D0 (en) Construction element
PL118349U1 (pl) Człon przesuwny
GB201118431D0 (en) No title#
GB0916935D0 (en) Fabricated crankshaft assemblies
GB0921748D0 (en) Switch-actuated arrangements
GB0901391D0 (en) Combination
GB0906696D0 (en) Combination
UA21009S (uk) Запальничка кремнієва